{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:29:53Z","timestamp":1793456993026,"version":"4.5.0"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific Research Project of the Jiangsu Provincial Health Commission","award":["M2021030"],"award-info":[{"award-number":["M2021030"]}]},{"name":"Research Project of Nanjing Medical University","award":["NMUB20220014"],"award-info":[{"award-number":["NMUB20220014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Influenza vaccines have been administered in Jiangsu Province. This study aimed to conduct a comprehensive retrospective analysis of influenza vaccine safety in the region from 2019 to 2023. Methods: Data were sourced from the Chinese National Adverse Events Following Immunization Information System (CNAEFIS) and Jiangsu Provincial Electronic Immunization Registries System (JSEIRS) systems. A comprehensive retrospective analysis was performed to calculate the incidence rates of adverse events following immunization (AEFI) and to identify potential safety signals through disproportionality analysis. Results: Out of 4,906,905 administered doses, 2080 AEFI cases were reported, yielding an overall incidence rate of 42.39 per 1,000,000 doses. Significantly higher rates were observed in children aged 6\u201335 months (71.03 per 1,000,000) and among recipients of trivalent vaccines (52.79 per 1,000,000) compared to quadrivalent vaccines (36.03 per 1,000,000). The vast majority of AEFIs were mild, common adverse reactions (94.47%, predominantly fever and local reactions), occurring predominantly within one day post-vaccination, while disproportionality analysis identified expected signals for common adverse reactions and rare local purulent infections. Conclusions: Overall, the findings affirm the vaccine\u2019s favorable safety profile, align with pre-marketing data, and underscore the critical role of continuous post-marketing surveillance in maintaining public confidence and monitoring the safety of both established and new vaccine formulations.<\/jats:p>","DOI":"10.3390\/vaccines13111154","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:33:17Z","timestamp":1762907597000},"page":"1154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Active Surveillance of Adverse Events Following Influenza Immunization in Jiangsu Province, China: A 2019\u20132023 Retrospective Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Zhiguo","family":"Wang","sequence":"first","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Department of Expanded Program on Immunization, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Public Health, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-9946","authenticated-orcid":false,"given":"Xun","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Department of Expanded Program on Immunization, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Hu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Department of Expanded Program on Immunization, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Department of Expanded Program on Immunization, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borong","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Department of Expanded Program on Immunization, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Department of Expanded Program on Immunization, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Children\u2019s Hospital of Nanjing Medical University, Nanjing 210093, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","first-page":"751","article-title":"Influenza: Diagnosis and Treatment","volume":"100","author":"Gaitonde","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2214-109X(19)30545-5","article-title":"Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Li, J., Zhang, Y., Zhang, X., and Liu, L. (2022). Influenza and Universal Vaccine Research in China. Viruses, 15.","DOI":"10.3390\/v15010116"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1002\/rmv.2243","article-title":"Influenza vaccines: Past, present, and future","volume":"32","author":"Kim","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1016\/j.vaccine.2020.07.007","article-title":"Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011\u20132019","volume":"38","author":"Moro","year":"2020","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2022.05.017","article-title":"National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20\/21","volume":"40","author":"Tsai","year":"2022","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2022057509","DOI":"10.1542\/peds.2022-057509","article-title":"Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial","volume":"150","author":"Essink","year":"2022","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/21645515.2017.1372069","article-title":"Ten years of experience and progress of electronic immunization registry system in Jiangsu Province, China","volume":"14","author":"Kang","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_9","first-page":"40","article-title":"Updating the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)","volume":"39","author":"Rust","year":"2010","journal-title":"Health Inf. Manag."},{"key":"ref_10","unstructured":"China Ministry of Health, Food and Drug Administration of China (2010). National Guideline for the Surveillance of Adverse Events Following Immunization, China Ministry of Health, Food and Drug Administration of China."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1900470","DOI":"10.2807\/1560-7917.ES.2020.25.22.1900470","article-title":"2017\/18 and 2018\/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network","volume":"25","author":"Bettinger","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e023263","DOI":"10.1136\/bmjopen-2018-023263","article-title":"Active surveillance of 2017 seasonal influenza vaccine safety: An observational cohort study of individuals aged 6 months and older in Australia","volume":"8","author":"Pillsbury","year":"2018","journal-title":"BMJ Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.vaccine.2022.02.088","article-title":"Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study","volume":"40","author":"Esposito","year":"2022","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/irv.13047","article-title":"Characterization of influenza seasonality in China, 2010-2018: Implications for seasonal influenza vaccination timing","volume":"16","author":"Liao","year":"2022","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.vaccine.2011.12.041","article-title":"Active surveillance for influenza vaccine adverse events: The integrated vaccine surveillance system","volume":"30","author":"Greece","year":"2012","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.vaccine.2016.06.064","article-title":"Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Moa","year":"2016","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2020.04.056","article-title":"Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety","volume":"38","author":"Glover","year":"2020","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1080\/21645515.2021.1964310","article-title":"Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine","volume":"17","author":"Lv","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, M., Gu, L., Zhang, Y., Zhou, H., Wang, Y., and Xu, Z.-X. (2024). A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1290975"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System","volume":"14","author":"Shu","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/014107687907200908","article-title":"Guillain-Barr\u00e9 syndrome: The swine influenza virus vaccine incident in the United States of America, 1976\u20131977: Preliminary communication","volume":"72","author":"Langmuir","year":"1979","journal-title":"J. R. Soc. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","article-title":"Guillain-Barr\u00e9 syndrome and influenza vaccines: A meta-analysis","volume":"33","author":"Sanz","year":"2015","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lopes, S.R.C., Perin, J.L.R., Prass, T.S., Carvalho, S.M.D., Lessa, S.C., and D\u00f3rea, J.G. (2018). Adverse Events Following Immunization in Brazil: Age of Child and Vaccine-Associated Risk Analysis Using Logistic Regression. Int. J. Environ. Res. Public Health, 15.","DOI":"10.3390\/ijerph15061149"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2017.03.035","article-title":"Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012\u201315","volume":"35","author":"Harris","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:34:13Z","timestamp":1762907653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vaccines13111154"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13111154","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}